文献速递哮喘

复合2型生物标志物策略与症状风险算法调整重症哮喘激素剂量的随机对照试验

Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial.
PubMed 文献 · Lancet Respir Med · 2020-09-08

这项多中心、单盲、平行组随机对照试验纳入301例重症哮喘成人患者,比较基于复合2型生物标志物(FeNO、血嗜酸性粒细胞、血清骨膜蛋白)的策略与标准化症状风险算法调整激素剂量。

要点

  • 生物标志物策略未在ITT人群中显著提高激素减量比例。
  • PP人群中生物标志物组减量比例显著高于对照组。
  • 生物标志物组减量患者未出现哮喘控制丧失。

核心结论

  • 基于生物标志物的激素调整未比对照策略使更多患者减少激素剂量。
  • 2型生物标志物低的重症哮喘患病率较低。

研究设计与样本

  • 多中心、单盲、平行组随机对照试验,纳入18-80岁重症哮喘成人,FeNO<45 ppb,来自英国12个专科中心。
  • 按4:1随机分配至生物标志物策略组(n=240)或对照组(n=61),ITT人群共301例。

主要发现

  • 两组次要结局无差异,生物标志物组减量患者无哮喘控制丧失。

关键数值与推荐

  • 生物标志物复合评分包括FeNO、血嗜酸性粒细胞和血清骨膜蛋白。
  • 对照组采用标准化症状风险算法调整激素剂量。

临床怎么用

  • 生物标志物策略可用于指导重症哮喘激素减量,但需注意患者依从性对结果的影响。
  • 对2型生物标志物低的患者,激素减量需谨慎评估。

局限性

  • 患者未遵循治疗建议是PP分析中失访的主要原因。
  • ITT人群中对照组样本量较小(n=61)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Asthma treatment guidelines recommend increasing corticosteroid dose to control symptoms and reduce exacerbations. This approach is potentially flawed because symptomatic asthma can occur without corticosteroid responsive type-2 (T2)-driven eosinophilic inflammation, and inappropriately high-dose corticosteroid treatment might have little therapeutic benefit with increased risk of side-effects. We compared a biomarker strategy to adjust corticosteroid dose using a composite score of T2 biomarkers (fractional exhaled nitric oxide [FENO], blood eosinophils, and serum periostin) with a standardised symptom-risk-based algorithm (control). METHODS: We did a single-blind, parallel group, randomised controlled trial in adults (18-80 years of age) with severe asthma (at treatment steps 4 and 5 of the Global Initiative for Asthma) and FENO of less than 45 parts per billion at 12 specialist severe asthma centres across England, Scotland, and Northern Ireland. Patients were randomly assigned (4:1) to either the biomarker strategy group or the control group by an online electronic case-report form, in blocks of ten, stratified by asthma control and use of rescue systemic steroids in the previous year. Patients were masked to study group allocation throughout the entirety of the study. Patients attended clinic every 8 weeks, with treatment adjustment following automated treatment-group-specific algorithms: those in the biomarker strategy group received a default advisory to maintain treatment and those in the control group had their treatment adjusted according to the steps indicated by the trial algorithm. The primary outcome was the proportion of patients with corticosteroid dose reduction at week 48, in the intention-to-treat (ITT) population. Secondary outcomes were inhaled corticosteroid (ICS) dose at the end of the study; cumulative dose of ICS during the study; proportion of patients on maintenance oral corticosteroids (OCS) at study end; rate of protocol-defined severe exacerbations per patient year; time to first severe exacerbation; number of hospital admissions for asthma; changes in lung function, Asthma Control Questionnaire-7 score, Asthma Quality of Life Questionnaire score, and T2 biomarkers from baseline to week 48; and whether patients declined to progress to OCS. A secondary aim of our study was to establish the proportion of patients with severe asthma in whom T2 biomarkers remained low when corticosteroid therapy was decreased to a minimum ICS dose. This study is registered with ClinicalTrials.gov, NCT02717689 and has been completed. FINDINGS: Patients were recruited from Jan 8, 2016, to July 12, 2018. Of 549 patients assessed, 301 patients were included in the ITT population and were randomly assigned to the biomarker strategy group (n=240) or to the control group (n=61). 28·4% of patients in the biomarker strategy group were on a lower corticosteroid dose at week 48 compared with 18·5% of patients in the control group (adjusted odds ratio [aOR] 1·71 [95% CI 0·80-3·63]; p=0·17). In the per-protocol (PP) population (n=121), a significantly greater proportion of patients were on a lower corticosteroid dose at week 48 in the biomarker strategy group (30·7% of patients) compared with the control group (5·0% of patients; aOR 11·48 [95% CI 1·35-97·83]; p=0·026). Patient choice to not follow treatment advice was the principle reason for loss to PP analysis. There was no difference in secondary outcomes between study groups and no loss of asthma control among patients in the biomarker strategy group who reduced their corticosteroid dose. INTERPRETATION: Biomarker-based corticosteroid adjustment did not result in a greater proportion of patients reducing corticosteroid dose versus control. Understanding the reasons for patients not following treatment advice in both treatment strategies is an important area for future research. The prevalence of T2 biomarker-low severe asthma was low. FUNDING: This study was funded, in part, by the Medical Research Council UK.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Heaney LG, Busby J, Hanratty CE, et al. Composite type-2 biomarker strategy versus a symptom-risk-based algorithm to adjust corticosteroid dose in patients with severe asthma: a multicentre, single-blind, parallel group, randomised controlled trial. Lancet Respir Med. 2020. PMID: 32916135. doi:10.1016/S2213-2600(20)30397-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。